Where Am I?
Tag Cloud

GREAT Week - Healthcare at Milan Expo

BritCham / CBBC
Event type GREAT Series organised by UK Trade & Investment
Date Tuesday, September 29th, 2015 to Wednesday, September 30th, 2015
Time 2 days
Open for All welcome
Contacts Ting.Qin@fco.gov.uk
Venue Milan Expo
Organiser External
Address Italy
Do you like this article? Share it with your friends!  
Like! Tweet! Weibo Share on LinkedIn
On the occasion of the Milan Expo Healthcare UK, the Life Sciences Organisation and the Department of Health are to launch together ‘The Future of Health’, a two-day initiative of events and networking opportunities that will take place in Milan on the 29th and 30th of September 2015. During these two days we will promote thought leadership conferences and workshops on digital health, genomics, regenerative medicine, infrastructure and dementia, involving high-profile stakeholders and a qualified UK audience of organisations from the private and public sectors. 
This event will give overseas stakeholders the opportunity to work with high profile UK executives to build partnerships and explore business deals. Also, the delegation will be provided with free entry to the Expo and fast track to the UK pavilion
For full details please see the introduction and attachments below, or contact the address above.
I – The healthcare and life sciences ecosystem: a strategic partnership
The UK has proven itself as one of the global leaders in healthcare and life sciences: leader in the field of DNA, genomics and personalised medicine, pioneer in in-vitro fertilisation and stem cell research for regenerative medicine, and inventor of the CAT and MRI scanners, now nurturing some of the most dynamic technology innovators. This world-leading excellence is cultivated by an ecosystem consisting of a three-way strategic partnership: the National Health Service (NHS), one of the most efficient healthcare systems in the world, an innovative and dynamic industry and a first class academia. 
The NHS: The UK was the first nation to establish universal healthcare coverage for all citizens when the NHS was founded in 1948. Healthcare has now been free at the point of access for over 65 years. The NHS is the world’s largest publically funded healthcare system and has become one of the most efficient healthcare providers globally. Underpinned by first-class training and education for healthcare professionals, the NHS has unrivalled expertise in meeting the complex healthcare demands of a diverse population. Academia and industry from around the globe work closely with the NHS to optimise clinical research for the benefit of patients in the UK. 
Industry: The strengths of the NHS are matched by the UK’s commercial healthcare sector, which is joined up and works successfully with the NHS to deliver efficient healthcare services in the UK and globally. UK industry is highly dynamic and innovative, providing integrated solutions and first-class clinical infrastructures to the NHS, and pursuing sustainability opportunities. Ultimately, UK industry is driving forward the role of the UK as a worldwide beacon for sustainable and cutting edge technological innovation. Life sciences is an area of significant development in UK industry - these companies make a contribution to the UK economy with projected growth of 36.4% between 2011-2016 for combined pharmaceutical, biotechnology, life sciences and healthcare equipment and supplies.
Academia: UK universities have a key role in driving forward change and innovation in healthcare and life sciences. As reported by the QS World University Rankings , the UK is home to four of the world’s top ten universities (Oxford, Cambridge, Imperial College London, University College London)  and is a global leader in clinical, pre-clinical and health subjects. The UK has a first-class clinical and medical education system, hosts the most prestigious and modern training facilities, and is open to partnerships to enhance training capacity internationally. This is in the context of escalating demand for healthcare professionals around the world: the World Health Organisation estimates a shortage of more than 4 million doctors, nurses, midwives and others. 
The UK’s healthcare and life sciences ecosystem supports the development of each partner, with shared learning, expertise and skills accelerating progress in addressing the major healthcare challenges of the 21st century. It also enables the NHS to spread and adopt new treatments and technologies to benefit patients and contribute to the thriving UK economy within a strong regulatory infrastructure: organisations such as Public Health England and the National Institute for Health and Care Excellence (NICE) are pivotal to creating a safe and sustainable health system.
II – Leading innovation and modernisation
The strength of the UK’s healthcare and life sciences ecosystem comes from the synergy between its partners and a consistent focus on making the benefits of the next generation of technology and research available to the patient and the public. Our greatest asset as a world leader in healthcare and life sciences is our ability to transform technology, treatments and ways of working, enabling us to find solutions to the challenges that all health systems face.
At the forefront in digital health: Driven by a combination of increasing cost pressures on health systems, the rise of chronic disease and the increasing role of technology in all facets of life, digital health is set to transform the delivery of care in the UK and across the world. It is the key to maintaining focus on the patient’s central role, while at the same time empowering doctors to deliver through innovative and cutting-edge solutions. 
The UK is at the forefront in the production of:
  • technology that can be worn on the body and installed at home to keep patients out of hospitals and empower them to take control of their health;
  • technology that gives clinicians, managers, and researchers the tools they need to deliver care, and develop more effective treatments; and
  • technology that makes health systems more efficient, by ensuring the seamless transfer and analysis of vital information.
The transformational potential of UK digital health has been illustrated by a number of initiatives, including the Whole System Demonstrator Programme, the world’s largest randomised controlled trial of telehealth and telecare. This programme involved over 6,191 nearly 6,200 patients and 238 General Practitioner (GP) practices across three sites in the UK,. Outcomes over 12 months were assessed in 3,154 telehealth users and control patients  with long-term conditions and pointed to a 20% reduction in emergency admissions and a 45% reduction in mortality rates. Other studies have revealed that electronic prescriptions can reduce total prescription error rates by 60%. The UK digital revolution in healthcare is putting at the fore the role of patients, supporting them in living independently, taking control and being at the centre of their own health and care.
Genomics and personalised medicine: The UK has often led the world in scientific breakthroughs and DNA was no exception. Crick and Watson discovered the double helix structure of DNA and it was double Noble prize winning scientist, Fred Sanger, who discovered how to sequence it. Now, the UK is leading the world in taking genomics from a research setting and into the NHS through the landmark 100,000 Genomes Project which is creating a lasting legacy for patients, the NHS and the UK economy through the sequencing of 100,000 genomes of patients with cancer or a rare disease by the end of 2017.  
The way in which the NHS is able to link a whole lifetime of medical records with a person’s genomic data and the fact that it can do this on a large scale is unique. The richness of this data will enable researchers, clinicians, scientists and industry to gain a better understanding of disease and will enable NHS patients to benefit from more personalised medicine. The potential of genomics is huge leading in time to new and more precise diagnostics for earlier diagnosis, new medical devices and new treatments and drugs. Genomics England, a company wholly owned and funded by the Department of Health is leading this project with the NHS – more details can be found at: www.genomicsengland.co.uk
Regenerative medicine: The UK is pioneering regenerative medicine, bringing together research and innovation to explore the possibility of replacing, engineering and regenerating human cells, tissues and organs, triggering the human body’s own repairing mechanisms. Regenerative medicine also offers the potential to change the course of chronic diseases, representing a new hope for many, by using stem cells to grow tissues and organs in the laboratory.
Regenerative medicine will tackle the challenge of an ageing population, reduce healthcare costs by providing a cure or better management for chronic or hard to treat diseases, and reduce the time and cost of drug development. In the UK, the Cell Therapy Catapult has been established to accelerate delivery of therapies to patients and will work with industry to deliver clinical trials, provide manufacturing expertise and infrastructure, access the NHS and clinical partners, and provide business and regulatory expertise.
Infrastructure for health: The UK is home to some of the world’s leading architectural, design, engineering and construction companies. They are global leaders, delivering cutting-edge healthcare infrastructure for healthcare providers around the world. Uniquely, the UK’s healthcare infrastructure sector has in-depth experience of working in partnership with the NHS, planning and delivering facilities and clinical services to deliver sustainable, high-quality patient-centred healthcare. 
UK companies are at the forefront of innovation for the healthcare sector, and have set internationally recognised standards, designing and building everything from multi-speciality hospitals serving entire cities, to primary care clinics for urban and rural communities. 
III – Towards our global role 
The UK healthcare and life sciences ecosystem is a global hub for international development and innovation. As the global partner of choice for many new emerging economies embarking on bold programmes of healthcare reform, the UK supports international development and promotes better and fairer healthcare across the world, and represents an exceptional opportunity for digital economies willing to invest in research and cutting-edge technologies. 
This document establishes the framework for the cooperation between the HMG organisations of Healthcare UK, the Department of Health and the Life Sciences Organisation which are involved in the delivery of one part of the UK’s programme at the 2015 Milan Expo. Through this engagement global projection of the UK healthcare and life sciences ecosystem will be channelled through a series of compelling propositions, part of the overall UK contribution to the development of global healthcare and life sciences. These propositions, representing the more advanced and state-of-the-art developments in the UK ecosystem are:
  • Digital Health
  • Personalised medicine
  • Regenerative medicine
  • Infrastructure for health (subject to availability of space/time in the programme)
Proposition focused events with international delegations, one-to-one meetings and other interactions will be organised and led in Milan by these HMG organisations. We will showcase the UK’s offer for the aforementioned propositions with the aim of raising awareness of the opportunities for trade and investment in the UK and of increasing the likeliness of commercial deals for UK organisations in these targeted markets.
A thorough planning of the operational delivery of this activity has begun and involves the relevant programme and geographic teams within the mentioned organisations, with the aim of supporting and promoting the role of the UK as a global leader in healthcare and life sciences on the occasion of the Expo.

please login first to get access to events registration!
Follow us